Strategies to manage hepatitis C virus infection disease burden - Volume 3

F. Z. Alfaleh; N. Nugrahini; M. Matičič; I. Tolmane; M. Alzaabi; B. Hajarizadeh; J. Valantinas; D. Y. Kim; B. Hunyady; F. Abaalkhail; Z. Abbas; A. Abdou; A. Abourached; F. Al Braiki; F. Al Hosani; K. Al Jaberi; M. Al Khatry; M. A. Al Mulla; H. Al Quraishi; A. Al Rifai; Y. Al Serkal; A. Alam; H. I. Alashgar; S. M. Alavian; S. Alawadhi; L. Al-Dabal; P. Aldins; A. S. Alghamdi; R. Al-Hakeem; A. A. Aljumah; A. Almessabi; A. N. Alqutub; K. A. Alswat; I. Altraif; N. Andrea; A. M. Assiri; M. A. Babatin; A. Baqir; M. T. Barakat; O. M. Bergmann; A. R. Bizri; A. Chaudhry; M. S. Choi; T. Diab; S. Djauzi; E. S. El Hassan; S. El Khoury; C. Estes; S. Fakhry; J. I. Farooqi; H. Fridjonsdottir; R. A. Gani; A. Ghafoor Khan; L. Gheorghe; A. Goldis; M. Gottfredsson; S. Gregorcic; J. Gunter; S. Hamid; K. H. Han; I. Hasan; A. Hashim; G. Horvath; R. Husni; W. Jafri; A. Jeruma; J. G. Jonasson; B. Karlsdottir; Y. S. Kim; Z. Koutoubi; L. A. Lesmana; V. Liakina; Y. S. Lim; A. Löve; M. Maimets; M. Makara; R. Malekzadeh; M. S. Memon; S. Merat; J. E. Mokhbat; F. H. Mourad; D. H. Muljono; A. Nawaz; S. Olafsson; S. Priohutomo; H. Qureshi; P. Rassam; H. Razavi; D. Razavi-Shearer; K. Razavi-Shearer; B. Rozentale; M. Sadik; K. Saeed; A. Salamat; R. Salupere; F. M. Sanai; A. Sanityoso Sulaiman; R. A. Sayegh; J. D. Schmelzer; A. I. Sharara; A. Sibley; M. Siddiq; A. M. Siddiqui; G. Sigmundsdottir; B. Sigurdardottir; D. Speiciene; A. Sulaiman; M. A. Sultan; M. Taha; J. Tanaka; H. Tarifi; G. Tayyab; M. Ud Din; M. Umar; J. Videčnik-Zorman; C. Yaghi; E. Yunihastuti; M. A. Yusuf; B. F. Zuberi; S. Blach

doi:10.1111/jvh.12474

Strategies to manage hepatitis C virus infection disease burden - Volume 3

F. Z. Alfaleh, N. Nugrahini, M. Matičič, I. Tolmane, M. Alzaabi, B. Hajarizadeh, J. Valantinas, D. Y. Kim, B. Hunyady, F. Abaalkhail, Z. Abbas, A. Abdou, A. Abourached, F. Al Braiki, F. Al Hosani, K. Al Jaberi, M. Al Khatry, M. A. Al Mulla, H. Al Quraishi, A. Al RifaiY. Al Serkal, A. Alam, H. I. Alashgar, S. M. Alavian, S. Alawadhi, L. Al-Dabal, P. Aldins, A. S. Alghamdi, R. Al-Hakeem, A. A. Aljumah, A. Almessabi, A. N. Alqutub, K. A. Alswat, I. Altraif, N. Andrea, A. M. Assiri, M. A. Babatin, A. Baqir, M. T. Barakat, O. M. Bergmann, A. R. Bizri, A. Chaudhry, M. S. Choi, T. Diab, S. Djauzi, E. S. El Hassan, S. El Khoury, C. Estes, S. Fakhry, J. I. Farooqi, H. Fridjonsdottir, R. A. Gani, A. Ghafoor Khan, L. Gheorghe, A. Goldis, M. Gottfredsson, S. Gregorcic, J. Gunter, S. Hamid, K. H. Han, I. Hasan, A. Hashim, G. Horvath, R. Husni, W. Jafri, A. Jeruma, J. G. Jonasson, B. Karlsdottir, Y. S. Kim, Z. Koutoubi, L. A. Lesmana, V. Liakina, Y. S. Lim, A. Löve, M. Maimets, M. Makara, R. Malekzadeh, M. S. Memon, S. Merat, J. E. Mokhbat, F. H. Mourad, D. H. Muljono, A. Nawaz, S. Olafsson, S. Priohutomo, H. Qureshi, P. Rassam, H. Razavi, D. Razavi-Shearer, K. Razavi-Shearer, B. Rozentale, M. Sadik, K. Saeed, A. Salamat, R. Salupere, F. M. Sanai, A. Sanityoso Sulaiman, R. A. Sayegh, J. D. Schmelzer, A. I. Sharara, A. Sibley, M. Siddiq, A. M. Siddiqui, G. Sigmundsdottir, B. Sigurdardottir, D. Speiciene, A. Sulaiman, M. A. Sultan, M. Taha, J. Tanaka, H. Tarifi, G. Tayyab, M. Ud Din, M. Umar, J. Videčnik-Zorman, C. Yaghi, E. Yunihastuti, M. A. Yusuf, B. F. Zuberi, S. Blach

Department of Infectology

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

8 Downloads (Pure)

Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).

Original language	English
Pages (from-to)	42-65
Number of pages	24
Journal	Journal of Viral Hepatitis
Volume	22
Issue number	S4
DOIs	https://doi.org/10.1111/jvh.12474
Publication status	Published - Dec 2015

Keywords*

diagnosis
disease burden
elimination
epidemiology
hepatitis C
hepatitis C virus
incidence
mortality
prevalence
scenarios
strategy
treatment

Field of Science*

3.1 Basic medicine
1.6 Biological sciences

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.12474

Strategies to manage hepatitis C virus infection disease burden volume 3Final published version, 4.75 MB

Cite this

Alfaleh, F. Z., Nugrahini, N., Matičič, M., Tolmane, I., Alzaabi, M., Hajarizadeh, B., Valantinas, J., Kim, D. Y., Hunyady, B., Abaalkhail, F., Abbas, Z., Abdou, A., Abourached, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., ... Blach, S. (2015). Strategies to manage hepatitis C virus infection disease burden - Volume 3. Journal of Viral Hepatitis, 22(S4), 42-65. https://doi.org/10.1111/jvh.12474

@article{47f8bd940d294889b65df97a83ccc534,

title = "Strategies to manage hepatitis C virus infection disease burden - Volume 3",

abstract = "The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).",

keywords = "diagnosis, disease burden, elimination, epidemiology, hepatitis C, hepatitis C virus, incidence, mortality, prevalence, scenarios, strategy, treatment",

author = "Alfaleh, {F. Z.} and N. Nugrahini and M. Mati{\v c}i{\v c} and I. Tolmane and M. Alzaabi and B. Hajarizadeh and J. Valantinas and Kim, {D. Y.} and B. Hunyady and F. Abaalkhail and Z. Abbas and A. Abdou and A. Abourached and {Al Braiki}, F. and {Al Hosani}, F. and {Al Jaberi}, K. and {Al Khatry}, M. and {Al Mulla}, {M. A.} and {Al Quraishi}, H. and {Al Rifai}, A. and {Al Serkal}, Y. and A. Alam and Alashgar, {H. I.} and Alavian, {S. M.} and S. Alawadhi and L. Al-Dabal and P. Aldins and Alghamdi, {A. S.} and R. Al-Hakeem and Aljumah, {A. A.} and A. Almessabi and Alqutub, {A. N.} and Alswat, {K. A.} and I. Altraif and N. Andrea and Assiri, {A. M.} and Babatin, {M. A.} and A. Baqir and Barakat, {M. T.} and Bergmann, {O. M.} and Bizri, {A. R.} and A. Chaudhry and Choi, {M. S.} and T. Diab and S. Djauzi and {El Hassan}, {E. S.} and {El Khoury}, S. and C. Estes and S. Fakhry and Farooqi, {J. I.} and H. Fridjonsdottir and Gani, {R. A.} and {Ghafoor Khan}, A. and L. Gheorghe and A. Goldis and M. Gottfredsson and S. Gregorcic and J. Gunter and S. Hamid and Han, {K. H.} and I. Hasan and A. Hashim and G. Horvath and R. Husni and W. Jafri and A. Jeruma and Jonasson, {J. G.} and B. Karlsdottir and Kim, {Y. S.} and Z. Koutoubi and Lesmana, {L. A.} and V. Liakina and Lim, {Y. S.} and A. L{\"o}ve and M. Maimets and M. Makara and R. Malekzadeh and Memon, {M. S.} and S. Merat and Mokhbat, {J. E.} and Mourad, {F. H.} and Muljono, {D. H.} and A. Nawaz and S. Olafsson and S. Priohutomo and H. Qureshi and P. Rassam and H. Razavi and D. Razavi-Shearer and K. Razavi-Shearer and B. Rozentale and M. Sadik and K. Saeed and A. Salamat and R. Salupere and Sanai, {F. M.} and {Sanityoso Sulaiman}, A. and Sayegh, {R. A.} and Schmelzer, {J. D.} and Sharara, {A. I.} and A. Sibley and M. Siddiq and Siddiqui, {A. M.} and G. Sigmundsdottir and B. Sigurdardottir and D. Speiciene and A. Sulaiman and Sultan, {M. A.} and M. Taha and J. Tanaka and H. Tarifi and G. Tayyab and {Ud Din}, M. and M. Umar and J. Vide{\v c}nik-Zorman and C. Yaghi and E. Yunihastuti and Yusuf, {M. A.} and Zuberi, {B. F.} and S. Blach",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons Ltd.",

year = "2015",

month = dec,

doi = "10.1111/jvh.12474",

language = "English",

volume = "22",

pages = "42--65",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "S4",

}

Alfaleh, FZ, Nugrahini, N, Matičič, M, Tolmane, I, Alzaabi, M, Hajarizadeh, B, Valantinas, J, Kim, DY, Hunyady, B, Abaalkhail, F, Abbas, Z, Abdou, A, Abourached, A, Al Braiki, F, Al Hosani, F, Al Jaberi, K, Al Khatry, M, Al Mulla, MA, Al Quraishi, H, Al Rifai, A, Al Serkal, Y, Alam, A, Alashgar, HI, Alavian, SM, Alawadhi, S, Al-Dabal, L, Aldins, P, Alghamdi, AS, Al-Hakeem, R, Aljumah, AA, Almessabi, A, Alqutub, AN, Alswat, KA, Altraif, I, Andrea, N, Assiri, AM, Babatin, MA, Baqir, A, Barakat, MT, Bergmann, OM, Bizri, AR, Chaudhry, A, Choi, MS, Diab, T, Djauzi, S, El Hassan, ES, El Khoury, S, Estes, C, Fakhry, S, Farooqi, JI, Fridjonsdottir, H, Gani, RA, Ghafoor Khan, A, Gheorghe, L, Goldis, A, Gottfredsson, M, Gregorcic, S, Gunter, J, Hamid, S, Han, KH, Hasan, I, Hashim, A, Horvath, G, Husni, R, Jafri, W, Jeruma, A, Jonasson, JG, Karlsdottir, B, Kim, YS, Koutoubi, Z, Lesmana, LA, Liakina, V, Lim, YS, Löve, A, Maimets, M, Makara, M, Malekzadeh, R, Memon, MS, Merat, S, Mokhbat, JE, Mourad, FH, Muljono, DH, Nawaz, A, Olafsson, S, Priohutomo, S, Qureshi, H, Rassam, P, Razavi, H, Razavi-Shearer, D, Razavi-Shearer, K, Rozentale, B, Sadik, M, Saeed, K, Salamat, A, Salupere, R, Sanai, FM, Sanityoso Sulaiman, A, Sayegh, RA, Schmelzer, JD, Sharara, AI, Sibley, A, Siddiq, M, Siddiqui, AM, Sigmundsdottir, G, Sigurdardottir, B, Speiciene, D, Sulaiman, A, Sultan, MA, Taha, M, Tanaka, J, Tarifi, H, Tayyab, G, Ud Din, M, Umar, M, Videčnik-Zorman, J, Yaghi, C, Yunihastuti, E, Yusuf, MA, Zuberi, BF & Blach, S 2015, 'Strategies to manage hepatitis C virus infection disease burden - Volume 3', Journal of Viral Hepatitis, vol. 22, no. S4, pp. 42-65. https://doi.org/10.1111/jvh.12474

TY - JOUR

T1 - Strategies to manage hepatitis C virus infection disease burden - Volume 3

AU - Alfaleh, F. Z.

AU - Nugrahini, N.

AU - Matičič, M.

AU - Tolmane, I.

AU - Alzaabi, M.

AU - Hajarizadeh, B.

AU - Valantinas, J.

AU - Kim, D. Y.

AU - Hunyady, B.

AU - Abaalkhail, F.

AU - Abbas, Z.

AU - Abdou, A.

AU - Abourached, A.

AU - Al Braiki, F.

AU - Al Hosani, F.

AU - Al Jaberi, K.

AU - Al Khatry, M.

AU - Al Mulla, M. A.

AU - Al Quraishi, H.

AU - Al Rifai, A.

AU - Al Serkal, Y.

AU - Alam, A.

AU - Alashgar, H. I.

AU - Alavian, S. M.

AU - Alawadhi, S.

AU - Al-Dabal, L.

AU - Aldins, P.

AU - Alghamdi, A. S.

AU - Al-Hakeem, R.

AU - Aljumah, A. A.

AU - Almessabi, A.

AU - Alqutub, A. N.

AU - Alswat, K. A.

AU - Altraif, I.

AU - Andrea, N.

AU - Assiri, A. M.

AU - Babatin, M. A.

AU - Baqir, A.

AU - Barakat, M. T.

AU - Bergmann, O. M.

AU - Bizri, A. R.

AU - Chaudhry, A.

AU - Choi, M. S.

AU - Diab, T.

AU - Djauzi, S.

AU - El Hassan, E. S.

AU - El Khoury, S.

AU - Estes, C.

AU - Fakhry, S.

AU - Farooqi, J. I.

AU - Fridjonsdottir, H.

AU - Gani, R. A.

AU - Ghafoor Khan, A.

AU - Gheorghe, L.

AU - Goldis, A.

AU - Gottfredsson, M.

AU - Gregorcic, S.

AU - Gunter, J.

AU - Hamid, S.

AU - Han, K. H.

AU - Hasan, I.

AU - Hashim, A.

AU - Horvath, G.

AU - Husni, R.

AU - Jafri, W.

AU - Jeruma, A.

AU - Jonasson, J. G.

AU - Karlsdottir, B.

AU - Kim, Y. S.

AU - Koutoubi, Z.

AU - Lesmana, L. A.

AU - Liakina, V.

AU - Lim, Y. S.

AU - Löve, A.

AU - Maimets, M.

AU - Makara, M.

AU - Malekzadeh, R.

AU - Memon, M. S.

AU - Merat, S.

AU - Mokhbat, J. E.

AU - Mourad, F. H.

AU - Muljono, D. H.

AU - Nawaz, A.

AU - Olafsson, S.

AU - Priohutomo, S.

AU - Qureshi, H.

AU - Rassam, P.

AU - Razavi, H.

AU - Razavi-Shearer, D.

AU - Razavi-Shearer, K.

AU - Rozentale, B.

AU - Sadik, M.

AU - Saeed, K.

AU - Salamat, A.

AU - Salupere, R.

AU - Sanai, F. M.

AU - Sanityoso Sulaiman, A.

AU - Sayegh, R. A.

AU - Schmelzer, J. D.

AU - Sharara, A. I.

AU - Sibley, A.

AU - Siddiq, M.

AU - Siddiqui, A. M.

AU - Sigmundsdottir, G.

AU - Sigurdardottir, B.

AU - Speiciene, D.

AU - Sulaiman, A.

AU - Sultan, M. A.

AU - Taha, M.

AU - Tanaka, J.

AU - Tarifi, H.

AU - Tayyab, G.

AU - Ud Din, M.

AU - Umar, M.

AU - Videčnik-Zorman, J.

AU - Yaghi, C.

AU - Yunihastuti, E.

AU - Yusuf, M. A.

AU - Zuberi, B. F.

AU - Blach, S.

PY - 2015/12

Y1 - 2015/12

N2 - The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).

AB - The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).

KW - diagnosis

KW - disease burden

KW - elimination

KW - epidemiology

KW - hepatitis C

KW - hepatitis C virus

KW - incidence

KW - mortality

KW - prevalence

KW - scenarios

KW - strategy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84945372576&partnerID=8YFLogxK

U2 - 10.1111/jvh.12474

DO - 10.1111/jvh.12474

M3 - Article

C2 - 26513447

AN - SCOPUS:84945372576

SN - 1352-0504

VL - 22

SP - 42

EP - 65

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - S4

ER -

Strategies to manage hepatitis C virus infection disease burden - Volume 3

Abstract

Keywords*

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this